Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEV-53275 in Persistent Eosinophilic Asthma
NCT04847674Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2021
- Primary completion
- Apr 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of varokibart in eosinophilic asthma (EA), sponsored by Teva Pharmaceutical Industries Ltd.. Started May 2021; status: terminated.
02
Drugs
varokibart
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT04847674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04847674.